Vera Therapeutics, Inc.

For the period ended Sep 30, 2026. Filed Nov 5, 2026.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2026 · Filed Nov 5, 2026

VERA$30.03-1.9%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Statements of Operations and Comprehensive Loss (unaudited)

Condensed Consolidated Statements of Operations and Comprehensive Loss

(in thousands, except share and per share amounts)

	Three Months EndedSeptember 30,		Nine Months EndedSeptember 30,
	2026	2025	2026	2025
Revenue:
Product revenue, net	$10,277	$—	$10,277	$—
Operating expenses:
Cost of sales	3,296	—	3,296	—
Research and development	41,253	56,473	187,344	155,946
Selling, general and administrative	61,430	27,459	152,961	65,321
Total operating expenses	105,979	83,932	343,601	221,267
Loss from operations	(95,702)	(83,932)	(333,324)	(221,267)
Other income (expense):
Interest income	4,336	5,736	16,039	18,962
Interest expense	(1,873)	(1,960)	(5,544)	(5,627)
Other expense, net	(472)	(137)	(1,387)	(586)
Total other income, net	1,991	3,639	9,108	12,749
Net loss	$(93,711)	$(80,293)	$(324,216)	$(208,518)
Other comprehensive loss:
Change in unrealized gains and losses on marketable securities	(301)	354	(1,490)	488
Comprehensive loss	$(94,012)	$(79,939)	$(325,706)	$(208,030)
Net loss per share attributable to common stockholders, basic and diluted	$(1.30)	$(1.26)	$(4.51)	$(3.27)
Weighted-average shares used in computing net loss per share attributable to common stockholders, basic and diluted	72,126,588	63,847,055	71,816,111	63,769,948

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.